ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ibrutinib

Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.

Drug pageIbrutinib: every studyMany companies study it; this page follows only the 74 they lead. All 264 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 14, 201774 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson364 open or runningphase 4since Jun 14, 2017May 14, 2012Dec 31, 2026phase 3 · NCT01804686
AbbVieits history only341 open or runningphase 4since Jun 5, 2017Feb 20, 2009May 10, 2027phase 4 · NCT03229200
Novartisits history only21 open or runningphase 2since May 21, 2019Mar 13, 2019Jun 30, 2027phase 2 · NCT03960840
BeOne Medicinesits history only10 open or runningphase 3since Feb 7, 2017Feb 7, 2017none ahead
Oncternal Therapeuticsits history only10 open or runningphase 3since Jun 9, 2022Jun 9, 2022none ahead

Also a collaborator on its studies: Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since May 14, 2012.

  1. Mar 2, 20152 phase 1 studiesNCT02381080, NCT02390609
  2. Jun 30, 2015Phase 1 study in Leukemia, LymphoidNCT02556892 · 8 enrolled · Japan
  3. Dec 18, 2015Phase 1 study in HealthyNCT02638116 · 20 enrolled · Belgium
  4. Mar 3, 2016Phase 3 study in Lymphoma, Non-HodgkinNCT02703272 · 72 enrolled · United States, Belgium, Brazil and more
  5. Jun 15, 2016Phase 1 study in HealthyNCT02841150 · 102 enrolled · United States
  6. Aug 19, 2016Phase 1 study in HealthyNCT02877225 · 103 enrolled · United States
  7. Jun 14, 2017Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03190330 · 75 enrolled · India
  8. Sep 29, 2017Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT03301207 · 25 enrolled · Poland, Spain
  9. Mar 6, 20182 phase 3 studiesNCT03462719, NCT03474679
  10. Jul 31, 2019Phase 4 study in Waldenstrom MacroglobulinemiaNCT04042376 · 17 enrolled · China
  11. Aug 19, 2019Phase 2 study in Waldenstrom MacroglobulinemiaNCT04062448 · 16 enrolled · Japan
  12. Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellNCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
  13. Jul 19, 2023Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05963074 · 333 enrolled · United States, Canada, Czechia and more
  14. Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01804686
  2. Dec 15, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05963074
  3. Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509

TargetBeta

BTK →read by rule
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 36 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more1By invitationJan 19, 2028120
NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Czechia and more2Active, not recruitingDec 15, 2027333
NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more2CompletedDec 6, 202336
NCT04062448Waldenstrom Macroglobulinemia · Japan2CompletedAug 24, 202116
NCT04042376Waldenstrom Macroglobulinemia · China4CompletedMar 19, 202417
NCT03474679Graft vs Host Disease · Japan3CompletedNov 29, 202119
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, Canada and more3Active, not recruitingFeb 26, 2021211
NCT03301207Leukemia, Lymphocytic, Chronic, B-Cell · Poland, Spain1CompletedJul 17, 201825
NCT03190330Leukemia, Lymphocytic, Chronic, B-Cell · India4CompletedMay 3, 202375
NCT02877225Healthy · United States1CompletedNov 11, 2016103
NCT02841150Healthy · United States1CompletedAug 2016102
NCT02703272Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more3TerminatedJun 11, 202172
NCT02638116Healthy · Belgium1CompletedMar 201620
NCT02556892Leukemia, Lymphoid · Japan1CompletedAug 20, 20188
NCT02390609Healthy · Belgium1CompletedNov 201540
NCT02381080Leukemia, Lymphocytic, Chronic, B-Cell · Canada, Russian Federation, Spain1CompletedJun 24, 201626
NCT02329847Hematologic Neoplasms · United States, Australia, Israel and more2CompletedFeb 9, 2022144
NCT02271438Healthy · Belgium1CompletedApr 201528
NCT02169180Lymphoma, Mantle-Cell · Japan2CompletedNov 201616
NCT01974440Lymphoma · United States, Argentina, Australia and more3CompletedMay 30, 2022403
NCT01973387Leukemia, Lymphocytic, Chronic, B-Cell · Australia, China, Malaysia and more3CompletedDec 1, 2015160
NCT01969266Healthy Volunteer · United States1CompletedNov 20138
NCT01866033Healthy Volunteer · Belgium1CompletedAug 20138
NCT01855750Lymphoma · United States, Argentina, Australia and more3CompletedFeb 26, 2018838
NCT01820936Healthy Volunteers · United States1CompletedJun 201352
NCT01804686Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3Active, not recruitingDec 31, 2026539
NCT01779791Lymphoma · United States, Australia, Belgium and more2CompletedMay 18, 2016110
NCT01776840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more3CompletedJun 30, 2021523
NCT01767948Hepatic Impairment · United States1CompletedNov 201330
NCT01763021Healthy Participants · United States1CompletedJan 201318
NCT01704963Neoplasms · Japan1CompletedNov 20, 201515
NCT01674322Healthy Participants · Belgium1CompletedSep 20126
NCT01646021Lymphoma, Mantle-Cell · Belgium, Brazil, Canada and more3CompletedJun 5, 2015280
NCT01626651Healthy · United States1CompletedAug 201221
NCT01611090Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Belgium and more3CompletedJan 23, 2019578
NCT01599949Lymphoma, Mantle-Cell · United States, Belgium, France and more2CompletedMay 2015120

How it is read

Names in the registry

  • “Ibrutinib”, 49 entries
  • “PCI-32765”, 10 entries
  • “ibrutinib”, 6 entries
  • “PCI-32765 (Ibrutinib)”, 2 entries
  • “SNX-5422 plus ibrutinib”, 2 entries

Codes read as this program: PCI32765.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.